Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microdose PK Study of Triazine Compounds WR826647, WR909388, and WR909390
NCT03436160Phase 1Completed
- Sponsor
- U.S. Army Medical Research and Development Command
- Start
- Aug 2018
- Primary completion
- Nov 2018
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in malaria comparing WR826647, WR909388 and WR909390 (3 arms). Primary endpoint: Pharmacokinetic parameters at 3 weeks. Started Aug 2018; status: completed.
02
Drugs
WR-826647WR909388WR909390
03
Conditions
malaria
Beyond the preview
Go deeper on NCT03436160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03436160.